Health Care [ 4/12 ] | Health Care Equipment & Supplies [ 43/72 ]
NYSE | Common Stock
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally.
It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.
The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy.
In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation.
Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure.
The company distributes its products through a direct sales force and independent distributors.
Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jul 24, 24 | 0.70 Increased by +6.06% | 0.69 Increased by +1.45% |
| Apr 25, 24 | 0.66 Increased by +6.45% | 0.64 Increased by +3.13% |
| Feb 6, 24 | 0.64 Increased by 0.00% | 0.64 |
| Oct 25, 23 | 0.59 Decreased by -3.28% | 0.59 |
| Jul 26, 23 | 0.66 Increased by +4.76% | 0.65 Increased by +1.54% |
| Apr 26, 23 | 0.62 Increased by +3.33% | 0.61 Increased by +1.64% |
| Jan 31, 23 | 0.64 Increased by +25.49% | 0.61 Increased by +4.92% |
| Oct 27, 22 | 0.61 Increased by +12.96% | 0.62 Decreased by -1.61% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 1.48 B Increased by +12.27% | 384.90 M Increased by +12.05% | Increased by +25.99% Decreased by -0.20% |
| Jun 30, 23 | 1.53 B Increased by +11.38% | 307.10 M Decreased by -24.43% | Increased by +20.07% Decreased by -32.15% |
| Mar 31, 23 | 1.46 B Increased by +8.83% | 340.50 M Decreased by -8.86% | Increased by +23.33% Decreased by -16.25% |
| Dec 31, 22 | 1.35 B Increased by +1.40% | 398.40 M Increased by +18.82% | Increased by +29.55% Increased by +17.18% |
| Sep 30, 22 | 1.32 B Increased by +0.67% | 343.50 M Increased by +1.00% | Increased by +26.04% Increased by +0.33% |
| Jun 30, 22 | 1.37 B Decreased by -0.15% | 406.40 M Decreased by -16.98% | Increased by +29.58% Decreased by -16.85% |
| Mar 31, 22 | 1.34 B Increased by +10.24% | 373.60 M Increased by +10.47% | Increased by +27.86% Increased by +0.20% |
| Dec 31, 21 | 1.33 B Increased by +11.58% | 335.30 M Increased by +8.34% | Increased by +25.22% Decreased by -2.91% |